QR Code

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

Abstract Background Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Xenopax, a novel and the only available humanized interleukin-2 (IL-2) receptor antagonist, has been approve...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Le-Qing Cao, Wen-Xuan Huo, Er-Lie Jiang, Yue-Wen Fu, Xiao-Jun Xu, Ping-Chong Lei, Ming-Feng Zhao, Zhi Chen, Shu-Xia Guo, Xiao-Bing Huang, Yan-Ming Zhang, Xian-Jing Wang, Guan-Chen Bai, Feng-Bo Jin, Qing-Sheng Li, Ming-Yang Deng, Hao Zhang, Xin-Feng Wang, Xiao-Jun Huang, Xiao-Dong Mo
Hōputu: Artigo
Reo:Inglês
I whakaputaina: KeAi Communications Co., Ltd. 2025-09-01
Rangatū:Military Medical Research
Ngā marau:
Xenopax
Acute graft-versus-host disease (aGVHD)
Steroid refractory (SR)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Urunga tuihono:https://doi.org/10.1186/s40779-025-00640-0
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite